Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
15.33%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.69%
median of 506 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Aptevo Therapeutics Inc.
Market Cap
$3.98M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.29M
Gross Margin
31.52%
TTM Avg
25.06%
3Y Avg
26.02%
5Y Avg
31.75%
Market Cap
$4.49M
Gross Margin
0.00%
TTM Avg
41.76%
3Y Avg
-40.89%
5Y Avg
-27.26%
Market Cap
$4.40M
Gross Margin
26.32%
TTM Avg
-195.38%
3Y Avg
-178.16%
5Y Avg
-96.97%
Market Cap
$4.50M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.47M
Gross Margin
36.10%
TTM Avg
40.19%
3Y Avg
41.87%
5Y Avg
47.28%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | $3.98M | 0.00% | 0.00% | 0.00% | 0.00% |
| GRI Bio, Inc. (GRI)vs › | $4.18M | N/A | 0.00% | 0.00% | 0.00% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.29M | 31.52% | 25.06% | 26.02% | 31.75% |
| Eocene Ltd. (EOCN)vs › | $3.59M | N/A | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.49M | 0.00% | 41.76% | -40.89% | -27.26% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.40M | 26.32% | -195.38% | -178.16% | -96.97% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.50M | 0.00% | 0.00% | 0.00% | 0.00% |
| Evogene Ltd. (EVGN)vs › | $3.39M | -6.25% | 25.54% | 36.71% | 34.86% |
| IceCure Medical Ltd (ICCM)vs › | $3.47M | 36.10% | 40.19% | 41.87% | 47.28% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.58M | 100.00% | 99.28% | 89.13% | 81.38% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | -56.26% |
| 2021-12-31 | -23.96% |
| 2021-09-30 | -41.05% |
| 2021-06-30 | -51.83% |
| 2021-03-31 | -121.48% |
| 2020-12-31 | -107.00% |
| 2020-09-30 | -207.18% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 32.06% |
| 2019-09-30 | 56.06% |
| 2019-06-30 | 18.68% |
| 2019-03-31 | 45.22% |
| 2018-12-31 | 29.69% |
| 2018-09-30 | 58.16% |
| 2018-06-30 | 62.88% |
| 2018-03-31 | 56.25% |
| 2017-12-31 | 32.72% |
| 2017-09-30 | 69.67% |
| 2017-06-30 | 45.22% |
| 2017-03-31 | 93.41% |
| 2016-12-31 | 9.37% |
| 2016-09-30 | 34.47% |
| 2016-06-30 | 35.80% |
| 2016-03-31 | 56.27% |
| 2015-12-31 | 36.80% |
| 2015-09-30 | 46.28% |
| 2015-06-30 | 37.39% |
| 2015-03-31 | 68.00% |
